Novel targets for VEGF-independent anti-angiogenic drugs

Bibliography

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27-31
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95
   PubMed Web of Science ®Google Scholar
• Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010;180:103-14
   PubMedGoogle Scholar
• Song S, Ewald AJ, Stallcup W, PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7(9):870-9
   PubMed Web of Science ®Google Scholar
• Sennino B, Falcon BL, McCauley D, Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67(15):7358-67
   PubMed Web of Science ®Google Scholar
• Potapova O, Laird AD, Nannini MA, Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5(5):1280-9
   PubMed Web of Science ®Google Scholar
• McCarty MF, Somcio RJ, Stoeltzing O, Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007;117(8):2114-22
   PubMed Web of Science ®Google Scholar
• Jayson GC, Parker GJ, Mullamitha S, Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23(5):973-81
   PubMed Web of Science ®Google Scholar
• Lu C, Shahzad MM, Moreno-Smith M, Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010;9(3):176-82
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjoquist M, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61(7):2929-34
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235-53
   PubMed Web of Science ®Google Scholar
• Nissen LJ, Cao R, Hedlund EM, Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117(10):2766-77
   PubMed Web of Science ®Google Scholar
• Kano MR, Morishita Y, Iwata C, VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118(Pt 16):3759-68
   PubMed Web of Science ®Google Scholar
• Taeger J, Moser C, Hellerbrand C, Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011;10(11):2157-67
   PubMed Web of Science ®Google Scholar
• Usui R, Shibuya M, Ishibashi S, Maru Y. Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep 2007;8(12):1155-561
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24):11851-8
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O'Dwyer PJ, Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18):2947-51
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323-30
   PubMed Web of Science ®Google Scholar
• Bianchi G, Loibl S, Zamagni C, Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20(7):616-24
   PubMed Web of Science ®Google Scholar
• Dy GK, Hillman SL, Rowland KM Jr, A front-line window of opportunity phase 2 study of sorafenib in patients with advanced non-small cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010;116(24):5686-93
   PubMed Web of Science ®Google Scholar
• Matei D, Sill MW, Lankes HA, Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;29(1):69-75
   PubMed Web of Science ®Google Scholar
• Bengala C, Bertolini F, Malavasi N, Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010;102(1):68-72
   PubMed Web of Science ®Google Scholar
• Williamson SK, Moon J, Huang CH, Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest Oncology Group Study S0420. J Clin Oncol 2010;28(20):3330-5
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ, A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117(1):37-40
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox JJ, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304(19):2154-60
   PubMed Web of Science ®Google Scholar
• Spigel DR, Burris HA III, Greco FA, Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(18):2582-9
   PubMed Web of Science ®Google Scholar
• Gridelli C, Morgillo F, Favaretto A, Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011;22(7):1528-34
   PubMed Web of Science ®Google Scholar
• Isaacs C, Herbolsheimer P, Liu MC, Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125(1):137-43
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Clin Oncol 2008;26(11):1810-16
   Web of Science ®Google Scholar
• Chien AJ, Aicardi J, Melisko ME, Phase I/II study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. J Clin Oncol 2010;28(15s Suppl):abstract 1067
   Google Scholar
• Wildiers H, Fontaine C, Vuylsteke P, Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123(2):463-9
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121(1):121-31
   PubMed Web of Science ®Google Scholar
• Dror Michaelson M, Regan MM, Oh WK, Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20(5):913-20
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Periman PO, Bernold D, Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21(2):319-24
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rosen LS, Marshall JL, Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25(30):4793-9
   PubMed Web of Science ®Google Scholar
• Hecht JR, Yoshino T, Mitchell EP, A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer: interim results. J Clin Oncol 2010;28(15s Suppl):abstract 3532
   Google Scholar
• Socinski MA, Novello S, Brahmer JR, Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26(4):650-66
   PubMed Web of Science ®Google Scholar
• Hensley ML, Sill MW, Scribner DR Jr, Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2009;115(3):460-5
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Oza AM, Chalchal HI, A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116(2):163-7
   PubMed Web of Science ®Google Scholar
• Machiels JP, Henry S, Zanetta S, Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28(1):21-8
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60(8):2178-89
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bajetta E, Valle J, Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011;29(15):2004-10
   PubMed Web of Science ®Google Scholar
• Hecht JR, Trarbach T, Hainsworth JD, Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011;29(15):1997-2003
   PubMed Web of Science ®Google Scholar
• Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685-93
   PubMed Web of Science ®Google Scholar
• Gauler TC, Besse B, Mauguen A, Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C, AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66(17):8715-21
   PubMed Web of Science ®Google Scholar
• Martin M, Roche H, Pinter T, Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12(4):369-76
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Vynnychenko I, Ichinose Y, An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced non squamous non-small cell lung cancer. J Clin Oncol 2011;29(Suppl):abstract LBA7512
   Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27(23):3794-801
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962-72
   PubMed Web of Science ®Google Scholar
• Taylor SK, Chia S, Dent S, A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010;15(8):810-18
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28(22):3562-9
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
   PubMed Web of Science ®Google Scholar
• Altorki N, Lane ME, Bauer T, Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28(19):3131-7
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27(19):3126-32
   PubMed Web of Science ®Google Scholar
• Eskens FA, Steeghs N, Verweij J, Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27(25):4169-76
   PubMed Web of Science ®Google Scholar
• Langenberg MH, Witteveen PO, Roodhart JM, Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2010;16(7):2187-97
   PubMed Web of Science ®Google Scholar
• Langenberg MH, Witteveen PO, Roodhart J, Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol 2011;22(11):2508-15
   PubMed Web of Science ®Google Scholar
• Albert DH, Tapang P, Magoc TJ, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5(4):995-1006
   PubMed Web of Science ®Google Scholar
• Toh H, Chen P, Carr BI, A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009;27(15s Suppl):abstract 4581
   Google Scholar
• Huynh H, Ngo VC, Fargnoli J, Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14(19):6146-53
   PubMed Web of Science ®Google Scholar
• Park JW, Finn RS, Kim JS, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17(7):1973-83
   PubMed Web of Science ®Google Scholar
• Garrett CR, Siu LL, El-Khoueiry A, Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer 2011;105(1):44-52
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-82
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kaneda H, Satoh T, Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9(10):2825-33
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Eschbach C, A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22(6):1374-81
   PubMed Web of Science ®Google Scholar
• Lee SH, Lopes de Menezes D, Vora J, In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11(10):3633-41
   PubMed Web of Science ®Google Scholar
• Angevin E, Grunwald V, Ravaud A, A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011;29(Suppl):abstract 4551
   Google Scholar
• Milowsky MI, Carlson GL, Shi MM, A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. J Clin Oncol 2011;29(Suppl):TPS 186
   Google Scholar
• Andre F, Bachelot TD, Campone M, A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. J Clin Oncol 2011;29(Suppl):abstract 508
   Google Scholar
• Ponzetto C, Bardelli A, Maina F, A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol 1993;13(8):4600-8
   PubMed Web of Science ®Google Scholar
• Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003;101(12):4816-22
   PubMed Web of Science ®Google Scholar
• Wojta J, Kaun C, Breuss JM, Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999;79(4):427-38
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 2011;20(9):1225-41
   PubMed Web of Science ®Google Scholar
• Munshi N, Jeay S, Li Y, ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9(6):1544-53
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Brunetto AT, Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29(10):1271-9
   PubMed Web of Science ®Google Scholar
• Schiller JH, Akerley WL, Brugger W, Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s Suppl):LBA 7502
   Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Berger R, Sella A, Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011;29(Suppl):abstract 5008
   Google Scholar
• Smith DC, Smith MR, Small EJ, Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol 2011;29(Suppl):abstract 127
   Google Scholar
• Wen PY, Prados M, Schiff D, Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol 2010;28(15s Suppl):abstract 2006
   Google Scholar
• Choueiri TK, Pal SK, Cabanillas ME, Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):abstract e13042
   Google Scholar
• Kurzrock R, Cohen EE, Sherman SI, Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2011;29(Suppl):abstract 5502
   Google Scholar
• Wakelee HA, Gettinger SN, Engelman JA, A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s Suppl):abstract 3017
   Google Scholar
• Eder JP, Heath E, Appleman L, Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007;25:abstract 3526
   Google Scholar
• Srinivasan R, Choueiri TK, Vaishampayan U, A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2008;26:abstract 5103
   Google Scholar
• Kanda S, Miyata Y, Mochizuki Y, Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 2005;65(15):6820-7
   PubMed Web of Science ®Google Scholar
• Hawighorst T, Skobe M, Streit M, Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002;160(4):1381-92
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001;158(2):563-70
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60
   PubMed Web of Science ®Google Scholar
• Suri C, Jones PF, Patan S, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87(7):1171-80
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79(2):213-23
   PubMed Web of Science ®Google Scholar
• Sato TN, Tozawa Y, Deutsch U, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376(6535):70-4
   PubMed Web of Science ®Google Scholar
• Mitsuhashi N, Shimizu H, Ohtsuka M, Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37(5):1105-13
   PubMed Web of Science ®Google Scholar
• Ahmad SA, Liu W, Jung YD, The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001;61(4):1255-9
   PubMed Web of Science ®Google Scholar
• Sfiligoi C, de Luca A, Cascone I, Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J Cancer 2003;103(4):466-74
   PubMed Web of Science ®Google Scholar
• Wong MP, Chan SY, Fu KH, The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000;29(1):11-22
   PubMed Web of Science ®Google Scholar
• Lind AJ, Wikstrom P, Granfors T, Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005;62(4):394-9
   PubMed Web of Science ®Google Scholar
• Hata K, Nakayama K, Fujiwaki R, Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004;93(1):215-22
   PubMed Web of Science ®Google Scholar
• Williams R. Discontinued drugs in 2007: oncology drugs. Expert Opin Investig Drugs 2008;17(3):1791-816
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Huang WQ, Yu J, Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 2000;83(9):1154-60
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Ahmad SA, Liu W, Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003;63(12):3370-7
   PubMed Web of Science ®Google Scholar
• Hawighorst T, Skobe M, Streit M, Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002;160(4):1381-92
   PubMed Web of Science ®Google Scholar
• Holopainen T, Huang H, Chen C, Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res 2009;69(11):4656-64
   PubMed Web of Science ®Google Scholar
• Fukuhara S, Sako K, Minami T, Differential function of Tie2 at cellcell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008;10(5):513-26
   PubMed Web of Science ®Google Scholar
• Falcon BL, Hashizume H, Koumoutsakos P, Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175(5):2159-70
   PubMed Web of Science ®Google Scholar
• Coxon A, Bready J, Min H, Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010;9(10):2641-51
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044-56
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Hansen VL, Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma. J Clin Oncol 2010;28(15s Suppl):abstract 5000
   Google Scholar
• Wenham RM, Leach JW, Scudder SA, Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin or topotecan in patients with advanced ovarian cancer. J Clin Oncol 2010;28(15s Suppl):abstract 5049
   Google Scholar
• Dieras V, Jassem J, Dirix LY, A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in patients with HER2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(Suppl):abstract 544
   Google Scholar
• Rini BI, Szczylik C, Tannir NM, AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer: a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 2011;29(Suppl 7):abstract 309
   Web of Science ®Google Scholar
• Eatock MM, Szanto J, Tebbutt NC, Randomized, double-blind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29(Suppl 4):abstract 66
   Web of Science ®Google Scholar
• Lu J, Rasmussen E, Navale L, Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: population pharmacokinetic/pharmacodynamic modeling to facilitate phase III dose selection. J Clin Oncol 2010;28(15s Suppl):abstract 5042
   Google Scholar
• Rosen LS, Mendelson DS, Cohen RB, First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin-2. J Clin Oncol 2010;28(15s Suppl):abstract 2524
   Google Scholar
• Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009;1792(10):954-73
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117-29; Erratum in: Nat Genet 2001;29(3):351
   PubMed Web of Science ®Google Scholar
• Franzen P, ten Dijke P, Ichijo H, Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993;75(4):681-92
   PubMed Web of Science ®Google Scholar
• Nakao A, Imamura T, Souchelnytskyi S, TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997;16(17):5353-62
   PubMed Web of Science ®Google Scholar
• Goumans MJ, Valdimarsdottir G, Itoh S, Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21(7):1743-53
   PubMed Web of Science ®Google Scholar
• Valdimarsdottir G, Goumans MJ, Rosendahl A, Stimulation of id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002;106(17):2263-70
   PubMed Web of Science ®Google Scholar
• Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002;100(13):4495-501
   PubMed Web of Science ®Google Scholar
• Park SO, Lee YJ, Seki T, ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008;111(2):633-42
   PubMed Web of Science ®Google Scholar
• Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117(26):6999-7006
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Chen E, Zhang L, Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 2011;71(4):1362-73
   PubMed Web of Science ®Google Scholar
• Mitchell D, Pobre EG, Mulivor AW, ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9(2):379-88
   PubMed Web of Science ®Google Scholar
• Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990;265(15):8361-4
   PubMed Web of Science ®Google Scholar
• Moren A, Ichijo H, Miyazono K. Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors. Biochem Biophys Res Commun 1992;189(1):356-62
   PubMed Web of Science ®Google Scholar
• Blanco FJ, Santibanez JF, Guerrero-Esteo M, Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005;204(2):574-84
   PubMed Web of Science ®Google Scholar
• ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11(1):79-89
   PubMed Web of Science ®Google Scholar
• Goff LW, Cohen RB, Berlin J, Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF{beta} receptor involved in tumor angiogenesis. J Clin Oncol 2011;29(Suppl 7):abstract 3009
   Google Scholar
• Borgstein NG, Sharma S, Bendell JC, Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma. J Clin Oncol 2010;28(15s Suppl):TPS 179
   Google Scholar
• Adelberg D, Apolo AB, Madan RA, A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011;29(Suppl 7):abstract e15070
   Web of Science ®Google Scholar
• Goldman JW, Gordon MS, Hurwitz H, A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl 7):abstract 3073
   Google Scholar
• Levin ER. Endothelins. N Engl J Med 1995;333(6):356-63
   PubMed Web of Science ®Google Scholar
• Spinella F, Rosano L, Di Castro V, Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002;277(31):27850-5
   PubMed Web of Science ®Google Scholar
• Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003;14(1):44-50
   PubMed Web of Science ®Google Scholar
• Kefford R, Beith JM, A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 2007;25(3):247-52
   PubMed Web of Science ®Google Scholar
• Kefford RF, Clingan PR, Brady B, A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 2010;9:69
   PubMed Web of Science ®Google Scholar
• Fukui R, Nishimori H, Hata F, Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer 2007;10(2):123-8
   PubMed Web of Science ®Google Scholar
• Nelson JB, Chan-Tack K, Hedican SP, Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56(4):663-8
   PubMed Web of Science ®Google Scholar
• Bagnato A, Cirilli A, Salani D, Growth inhibition of cervix carcinoma cell in vivo by endothelin A receptor blockade. Cancer Res 2002;62(22):6381-4
   PubMed Web of Science ®Google Scholar
• Carducci MA, Padley RJ, Breul J, Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, phase II, placebo controlled trial. J Clin Oncol 2003;21(4):679-89
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson PA, A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-66
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Haura E, Rodriguez FA, Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008;14(5):1464-9
   PubMed Web of Science ®Google Scholar
• Manola J, Carducci M, Nair S, Phase II ECOG trial of atrasentan in advanced renal cell carcinoma. J Clin Oncol 2007;25:abstract 5102
   Google Scholar
• Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009;20(2):83-8
   PubMed Web of Science ®Google Scholar
• James ND, Caty A, Payne H, Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010;106(7):966-73
   PubMed Web of Science ®Google Scholar
• Nelson JB, Fizazi K, Miller K, Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer. J Clin Oncol 2011;29(Suppl 7):abstract 117
   Web of Science ®Google Scholar
• Trump DL, Payne H, Miller K, Safety and efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone-resistant prostate cancer: results of a phase I study. J Clin Oncol 2010;28(15s Suppl):abstract 4664
   Google Scholar
• Zelinski DP, Zantek ND, Stewart JC, EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61(5):2301-6
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Coffman K, Azimi M, Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41(4):275-80
   PubMed Web of Science ®Google Scholar
• D'Amico TA, Aloia TA, Moore MB, Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001;72(4):1144-8
   PubMed Web of Science ®Google Scholar
• Ogawa K, Pasqualini R, Lindberg RA, The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19(52):6043-52
   PubMed Web of Science ®Google Scholar
• Thaker PH, Deavers M, Celestino J, EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10(15):5145-50
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Riese DJ II, Kinch MS. C-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002;1(1):79-87
   PubMed Web of Science ®Google Scholar
• Cheng N, Brantley DM, Liu H, Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002;1(1):2-11
   PubMed Web of Science ®Google Scholar
• Hess AR, Seftor EA, Gardner LM, Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61(8):3250-5
   PubMed Web of Science ®Google Scholar
• Landen CN Jr, Lu C, Han LY, Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98(21):1558-70
   PubMed Web of Science ®Google Scholar
• Gerety SS, Anderson DJ. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 2002;129(6):1397-410
   PubMed Web of Science ®Google Scholar
• Yavrouian EJ, Sinha UK, Rice DH, The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008;134(9):985-91
   PubMed Web of Science ®Google Scholar
• Li M, Zhao ZW, Zhang Y, Xin Y. Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. Dig Dis Sci 2011;56(3):698-706
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Mangala LS, Stone RL, Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010;9(8):2377-88
   PubMed Web of Science ®Google Scholar
• Alam SM, Fujimoto J, Jahan I, Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers. Gynecol Oncol 2009;114(1):84-8
   PubMed Web of Science ®Google Scholar
• Alam SM, Fujimoto J, Jahan I, Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann Oncol 2007;18(3):485-90
   PubMed Web of Science ®Google Scholar
• Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006;8(8):815-25
   PubMed Web of Science ®Google Scholar
• Dopeso H, Mateo-Lozano S, Mazzolini R, The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res 2009;69(18):7430-8
   PubMed Web of Science ®Google Scholar
• Djokovic D, Trindade A, Gigante J, Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 2010;10:641
   PubMed Web of Science ®Google Scholar
• Kertesz N, Krasnoperov V, Reddy R, The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4- EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006;107(6):2330-8
   PubMed Web of Science ®Google Scholar
• Scehnet JS, Ley EJ, Krasnoperov V, The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009;113(1):254-63
   PubMed Web of Science ®Google Scholar
• Krasnoperov V, Kumar SR, Ley E, Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 2010;176(4):2029-38
   PubMed Web of Science ®Google Scholar
• Agarwal N, Sahu M, Abhyankar DJ, A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. J Clin Oncol 2011;29:abstract e15077
   Web of Science ®Google Scholar
• Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007;17(1):52-9
   PubMed Web of Science ®Google Scholar
• Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007;13(9):389-95
   PubMed Web of Science ®Google Scholar
• Noguera-Troise I, Daly C, Papadopoulos NJ, Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444(7122):1032-7
   PubMed Web of Science ®Google Scholar
• Patel NS, Dobbie MS, Rochester M, Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006;12(16):4836-44
   PubMed Web of Science ®Google Scholar
• Hu W, Lu C, Stone RL, Biologic role of tumor and endothelial delta-like ligand 4 in ovarian cancer. Gynecol Oncol 2011;120:S35-6
   Web of Science ®Google Scholar
• Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67(5):1879-82
   PubMed Web of Science ®Google Scholar
• Vermeulen PB, Colpaert C, Salgado R, Liver metastases from colorectal denocarcinomas grow in three patterns with different angiogenesis and esmoplasia. J Pathol 2001;195(3):336-42
   PubMed Web of Science ®Google Scholar
• Pezzella F, Pastorino U, Tagliabue E, Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997;151(5):1417-23
   PubMed Web of Science ®Google Scholar
• Maniotis AJ, Folberg R, Hess A, Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155(3):739-52
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3(6):411-21
   PubMed Web of Science ®Google Scholar
• Dome B, Hendrix MJ, Paku S, Alternative vascularisation mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007;170(1):1-15
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468(7325):824-8
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40
   PubMedGoogle Scholar